Latest Options News

Immutep Limited’s Phase II EFTISARC-NEO trial reveals a novel immunotherapy combo delivering a striking 51.5% tumour response in soft tissue sarcoma patients, alongside robust immune activation signals.

Mount Gibson Iron has announced a further extension of its on-market share buy-back program, now set to run until November 2026, maintaining flexibility amid uncertain market conditions.

Xero Limited reported a robust first half of FY26 with 20% revenue growth and a 42% jump in net profit, driven by the strategic acquisition of Melio and expanded AI capabilities.

Enegex Limited has completed its acquisition of Famien Resources, adding a substantial gold exploration portfolio in Côte D’Ivoire, alongside a $5 million capital raise to support its growth ambitions.

TT Investments has confirmed that its all-cash takeover offer for 360 Capital Group will close on 13 November 2025 without extension, marking a decisive moment for the ASX-listed investment manager.

WCM Global Growth Limited has announced an increased fully franked dividend for Q1 FY2026, alongside a progressive dividend policy forecasting steady growth through September 2026.

WCM Global Growth Limited has announced a fully franked quarterly dividend of AUD 0.0209 per share, accompanied by a dividend reinvestment plan offering a 3% discount on new shares.

Tartana Minerals has inked a non-binding Letter of Intent with Alt Resources for up to $5 million in non-dilutive financing, structured to align repayments with copper production and prices. This deal aims to optimize existing operations and fund expansion through the Mungana processing plant.

Reward Minerals has signed a binding Letter of Intent to acquire the Copper Lance Project in Newfoundland, a promising volcanogenic massive sulphide deposit with historic high-grade copper and silver results. The company plans to fast-track exploration to unlock value in this underexplored Canadian terrane.

The FDA's removal of the black box warning on hormone replacement therapies marks a pivotal shift for Mayne Pharma, potentially unlocking new market opportunities and reshaping women’s health treatment.

Radiopharm Theranostics has successfully enrolled the second cohort in its Phase 1 trial of 177Lu-RAD204, with the Data Safety Monitoring Committee greenlighting a dose increase to 90mCi for the third cohort. Early results show promising tumor targeting and safety in multiple advanced cancers.

Skylark Minerals has agreed to acquire a portfolio of gold projects in Côte d’Ivoire, including the flagship Zaranou Project with a JORC-compliant inferred resource of 364,600 ounces. This deal positions Skylark as a significant emerging player in West Africa’s gold sector.